Literature DB >> 28673745

High Altitude Pulmonary Edema in a Mining Worker With an Abnormal Rise in Pulmonary Artery Pressure in Response to Acute Hypoxia Without Prior History of High Altitude Pulmonary Edema.

Almaz Ch Akunov1, Meerim A Sartmyrzaeva1, Abdirashit M Maripov1, Kubatbek Muratali Uulu1, Argen T Mamazhakypov2, Akylbek S Sydykov2, Akpay Sh Sarybaev3.   

Abstract

High altitude pulmonary edema (HAPE) is a potentially life-threatening form of noncardiogenic pulmonary edema that may develop in otherwise healthy individuals upon ascent to high altitude. A constitutional susceptibility has been noted in some individuals, whereas others appear not to be susceptible at all. In our report, we present a case of HAPE triggered by concurrent respiratory tract infection and strenuous exercise in a mining worker with an abnormal rise in pulmonary artery pressure in response to acute hypoxia, without a prior history of HAPE during almost a year of commuting between high altitude and lowland areas.
Copyright © 2017 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  case report; high altitude pulmonary edema; overexercise; respiratory tract infection; susceptibility

Mesh:

Year:  2017        PMID: 28673745     DOI: 10.1016/j.wem.2017.04.003

Source DB:  PubMed          Journal:  Wilderness Environ Med        ISSN: 1080-6032            Impact factor:   1.518


  2 in total

1.  HSPA1A gene polymorphism rs1008438 is associated with susceptibility to acute mountain sickness in Han Chinese individuals.

Authors:  Zhicheng Liu; Hong Chen; Ting Xu; Xiaomei Wang; Chunyan Yao
Journal:  Mol Genet Genomic Med       Date:  2020-06-01       Impact factor: 2.183

Review 2.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Abdirashit Maripov; Djuro Kosanovic; Norbert Weissmann; Hossein Ardeschir Ghofrani; Akpay Sh Sarybaev; Ralph Theo Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.